Cellectar Biosciences, Inc. CLRB
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.31% | 10.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.20% | 1.82% | |||
| Operating Income | -24.20% | -1.82% | |||
| Income Before Tax | -22.58% | -6.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.58% | -6.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.58% | -6.77% | |||
| EBIT | -24.20% | -1.82% | |||
| EBITDA | -24.74% | -1.76% | |||
| EPS Basic | 57.51% | -3.46% | |||
| Normalized Basic EPS | 57.51% | -3.46% | |||
| EPS Diluted | 57.25% | -3.46% | |||
| Normalized Diluted EPS | 57.51% | -3.46% | |||
| Average Basic Shares Outstanding | 188.48% | 3.20% | |||
| Average Diluted Shares Outstanding | 188.48% | 3.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||